Jump to content

Levonantradol: Difference between revisions

From Wikipedia, the free encyclopedia
Content deleted Content added
No edit summary
No edit summary
Line 2: Line 2:
|IUPAC_name = [(6S,6aR,9R,10aR)-9-hydroxy-6-methyl-3-[(2R)-5-phenylpentan-2-yl] oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl] acetate
|IUPAC_name = [(6S,6aR,9R,10aR)-9-hydroxy-6-methyl-3-[(2R)-5-phenylpentan-2-yl] oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl] acetate
| image = Levonantradol.png
| image = Levonantradol.png
| width= 160
| width= 200
| CAS_number= 71048-87-8
| CAS_number= 71048-87-8
| ATC_prefix=
| ATC_prefix=

Revision as of 03:38, 26 April 2007

Levonantradol
Identifiers
  • [(6S,6aR,9R,10aR)-9-hydroxy-6-methyl-3-[(2R)-5-phenylpentan-2-yl] oxy-5,6,6a,7,8,9,10,10a-octahydrophenanthridin-1-yl] acetate
CAS Number
PubChem CID
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC27H35NO4
Molar mass437.571 g/mol g·mol−1

Levonantradol (Nantrodolum) is a synthetic cannabinoid analog of dronabinol (Marinol). It exhibits antiemetic and analgesic effects, most likely by binding to and activating CB1 and CB2 cannabinoid receptors. Levonantradol is not currently used in medicine as dronabinol or nabilone are felt to be more useful for most conditions, however it is widely used in research into the potential therapeutic applications of cannabinoids. [1] [2] [3]


References

  1. ^ Tramer MR, Carroll D, Campbell FA, Reynolds DJ, Moore RA, McQuay HJ. Cannabinoids for control of chemotherapy induced nausea and vomiting: quantitative systematic review. British Medical Journal 2001 Jul 7;323(7303):16-21.
  2. ^ Campbell FA, Tramer MR, Carroll D, Reynolds DJ, Moore RA, McQuay HJ. Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. British Medical Journal. 2001 Jul 7;323(7303):13-6.
  3. ^ Ben Amar M. Cannabinoids in medicine: A review of their therapeutic potential. Journal of Ethnopharmacology. 2006 Apr 21;105(1-2):1-25.


Catagory:Cannabinoids